Although exposure to delta-9-tetrahydrocannabinol (THC) is perceived to be relatively harmless, mounting evidence has begun to show that it is associated with a variety of cognitive deficits, including poor decision making. THC-induced impairments in decision making are thought to be the result of cannabinoid CB1 receptor activation, and although clinical literature suggests that chronic activation via THC contributes to perturbations in decision making, acute CB1 receptor modulation has yielded mixed results. Using an animal model to examine how CB1-specific ligands impact choice biases would provide significant insight as to how recruitment of the endocannabinoid system may influence decision making. Here, we used the rat gambling task (rGT), a validated analogue of the human Iowa Gambling Task, to assess baseline decision making preferences in male Wistar rats. After acquisition rGT performance was measured. Animals were challenged with the CB1 receptor antagonist rimonabant, the partial agonist THC, and the synthetic agonist WIN55,212-2. Animals were also treated acutely with the fatty acid amide hydrolase (FAAH) inhibitor URB597 to selectively upregulate the endocannabinoid anandamide. Blockade of the CB1 receptor produced a trend improvement in decision making in animals who preferred the advantageous task options, yet left choice unaffected in risk-prone rats. Neither CB1 receptor agonist had strong effects on decision making, but a high dose THC decreased premature responses, whereas WIN55,212-2 did the opposite. URB597 did not affect task performance. These results indicate that although chronic CB1 receptor activation may be associated with impaired decision making, acute modulation has modest effects on choice and instead may play a substantive role in regulating impulsive responding.
Introduction
Legislation permitting cannabis use is on the rise in several western countries, leading to greater consumption (United Nations, 2015) . Use of the active ingredient in cannabis, Δ9-tetrahydrocannabinol (THC), is widely viewed to be relatively harmless and having little to no addiction potential (United Nations, 2015) . However, despite social acceptance, recent studies portray a different picture of THC, with use being associated with increased prevalence of a variety of psychiatric phenotypes including addiction, depression, anxiety, and schizophrenia (Renard et al., 2014) . Interestingly, poor cost/benefit decision making has been implicated in each of these conditions (Bechara, 2005; Cella et al., 2010; Zhang et al., 2015; Pedersen et al., 2017) , suggesting deficits in choice may serve as a common contributor to expression of these psychopathologies, and may be affected by THC consumption. Indeed, data from studies using the Iowa Gambling Task (IGT), a clinical paradigm designed to operationalize cost/benefit decision making, show chronic cannabis use is also associated with maladaptive choice (Bolla et al., 2005) . Therefore, there may be overlapping circuitries that are affected by THC which culminates in psychiatric illness and poor decision making. Investigating the role of cannabinoid CB1 receptor activity, the main target of THC, on decision making may provide unique insight into the etiology of these disorders, and contribute to development of treatments.
Though chronic cannabis experience is associated with impaired decision making, it is unclear what aspect of decision making is the most affected, such as motivation or value processing, and whether effects on choice are present even after acute THC experience. One human study found acute THC exposure reduced effort-based decision making, especially when probabilities of winning were low, suggesting THC fosters an a-motivational state (Lawn et al., 2016) . This data is also supported by animal studies (Silveira et al., 2017) , where THC dosedependently reduced willingness to expend cognitive effort. Another study found acute THC administration in occasional users produced impairments in reaction time on a monetary incentive delay task, but was also associated with greater orbitofrontal gyrus activation during reward anticipation (Van Hell et al., 2012) , indicating THC may impact sensitivity to reward. However, results from human reports are mixed on the recruitment of the endocannabinoid system and probabilistic decision making; results from abstinent cannabis users with a history of heavy intake showed impaired decision making on the IGT, but other studies found no impairments after acute THC administration or in active heavy users (Bolla et al., 2005; Ramaekers et al., 2006; Cousijn et al., 2013) . These data suggest cognitive impairment after THC experience may be due to length of use rather than general deleterious effects of the drug. However, another explanation is that the variable effects seen in humans may be due to individual differences in activation of brain regions important for reward evaluation and decision making (Cousijn et al., 2013) , suggesting that differences in reward processing may explain discrepancies in responding to THC, and potentially even demonstrate a vulnerability to cognitive deficits after acute THC exposure.
A significant challenge when evaluating human data are the myriad of social, cultural, and environmental factors which can influence results. Animal models provide a means to investigate the causal relationship between behavior and its neurobiological substrates (Potenza, 2009) . In recent years, using a rodent analogue of the IGT, the rat gambling task (rGT), we have shown animals produce decision making profiles akin to humans, and have explored the influence of several neurotransmitter systems on risky decision making (Zeeb et al., 2009; De Visser et al., 2011; Winstanley and Clark, 2016 ). Furthermore, the task measures additional variables, such as impulse control and motivation, giving the paradigm greater behavioral resolution and, making it ideally suited to study how different neurobiological mechanisms contribute to distinct cognitive processes. Indeed, we have found previously that serotonin and dopamine modulate different aspects of rGT performance (Zeeb et al., 2009) . Interestingly, activation of the cannabinoid CB1 receptor mediates dopaminergic output (French, 1997) and dorsal raphe activity (Haj-Dahmane and Shen, 2009) , influences responding to food and drug rewards (Sanchis-Segura et al., 2004; De Vries et al., 2005) , and affects the maturation of key regions implicated in decision making, including the prefrontal cortex and amygdala, during development (Parsons and Hurd, 2015; Winstanley, 2011, 2013) . Therefore, THC may influence decision making by mediating dopaminergic and serotonergic mechanisms, although cannabinoid-mediated effects on glutamate and GABA transmission could also impact decision making (Colizzi et al., 2016; Piomelli, 2003) . Another powerful asset of the rGT is the ability to assess individual differences in decision making. There is an emerging body of preclinical work that has shown baseline patterns of risky choice can influence responding to drugs of abuse (Ferland and Winstanley, 2017; Mitchell et al., 2014) . It is possible that the variable effects seen after THC administration may be representative of differential responding to rewards, and animals prone to select large, risky rewards may be more sensitive to CB1 activation. Using the rGT, we can assess how animals respond to acute administration of THC and other CB1 agents, and perhaps clarify why drugs like THC and synthetic cannabinoids produce mixed effects in humans.
To explore the role of the CB1 receptor in decision making, this study employed acute administration of CB1 receptor agonists THC and WIN55,212-2, the CB1 receptor antagonist rimonabant, and the fatty acid amide hydrolase (FAAH) inhibitor URB-597 to determine the influence of cannabinoid CB1 receptor activity on choice preferences, impulsive action, and motivation in male Wistar rats. We also examined the potential role of individual risk preference in the response to these drugs. To replicate previous findings obtained in other rat strains, we administered acute doses of the psychostimulant amphetamine. We hypothesized that administration of CB1 receptor agonists would impair, while CB1 antagonism would improve, task performance, and individual sensitivity to risk would mediate the behavioral outcome to CB1 modulation.
Methods

Subjects
In total thirty-two male Wistar rats were obtained from Harlan CPB (Horst, The Netherlands). At the start of the experiments animals weighed approximately 250 g, and were housed two per cage in macrolon cages (42.5 × 26.6 × 18.5 cm; length × width × height) under a reversed 12 h light/dark cycle (lights on at 7.00 PM) at controlled room temperature (21 ± 2°C) and relative humidity (60 ± 15%). Animals were maintained at approximately 90% of their free-feeding weight, starting one week prior to the start of experiments by restricting the amount of standard rodent food chow. Water was available ad libitum throughout the entire experiment. All experiments were conducted with the approval of the animal ethical committee of the VU University and VU University Medical Center Amsterdam, the Netherlands, and all efforts were made to minimize animal suffering.
Apparatus
Experiments were conducted in sixteen identical rat five-hole nose poke operant chambers with stainless steel grid floors (MED-NPW-5 L, Med Associates Inc., Fairfax, VT, USA) housed in sound-insulating and ventilated cubicles. Set in the curved wall of each box was an array of five circular holes 2.54 cm in diameter, 2.2 cm deep and 2.25 cm above floor level. Each hole was equipped with an infrared detector located across each nose poke unit 1.0 cm from the front, and a yellow LED stimulus light (6.4 mm in diameter). Rodent Dustless Precision Pellets® (45 mg, F0021, Bio-Serv, Frenchtown, NJ, USA) were delivered at the opposite wall via a dispenser into a food tray. In addition, the chamber could be illuminated by a white house light. A computer equipped with MED-PC version 1.17 (Med Associates Inc., Fairfax, VT, USA) controlled experimental sessions and recorded data. Animals were trained once daily from Monday to Friday, during the dark phase of the light/dark cycle.
Behavioral procedure
Two cohorts of animals (n = 16 each) were trained in the rGT as described below.
Upon establishment of a stable baseline, animals in cohort 1 were pharmacologically challenged with the cannabinoid CB1 receptor antagonist rimonabant, the synthetic cannabinoid CB1 receptor agonist WIN55,212-2, and the cannabinoid CB1 receptor agonist Δ9-tetrahydrocannabinol (THC). In cohort 2, the effects of the FAAH inhibitor URB597 and the psychostimulant amphetamine were examined. For both cohorts, identical training protocols were followed.
Habituation
Animals were habituated to food pellet rewards and the operant chamber over 7 days. On days 1-3, ten food pellets were placed in each home cage. Food restriction began on day 3. On days 4 and 5, animals were placed in the operant chamber for 20 min each day with the house light on and five food pellets in the food tray. On days 6 and 7, animals were placed in the operant chamber and 75 pellets were dispensed on average every 15 s, so that animals would associate the sound of pellet delivery with reward.
rGT training
After habituation as described above, animals were subjected to a series of rGT-specific training protocols, described in detail in previously published reports (Zeeb et al., 2009; Zeeb and Winstanley, 2011) . As previously described, the rGT mimics the human Iowa Gambling Task by presenting four choices with different reward and punishment amounts and probabilities (Bechara et al., 1994; Zeeb et al., 2009) . First, the animals were trained to make a nose-poke response in an illuminated hole in order to earn a reward in the food tray; the illuminated hole varied between trials across holes 1, 2, 4, and 5. Each session consisted of 100 trials and lasted for approximately 30 min. This phase of training involved three stages, with stimulus duration (i.e. light on in the nose-poke hole), limited hold (i.e. delay between stimulus light extinction and trial end), and the inter-trial interval programmed for 30 s, 30 s, and 2 s, respectively, in stage 1, then 20 s, 20 s, and 2 s in stage 2, and 10 s, 10 s, and 5 s in stage 3. Correct responses were those made at the illuminated hole. Omissions were counted when no response was made during stimulus illumination or the limited hold. The criteria for progressing to the next stage were completion of 100 trials with ≥80% correct and ≤ 20% omitted. Animals not meeting these criteria after three sessions of stage 1 training were placed on an additional training protocol to ensure that they learned to respond at illuminated nose-poke holes to earn reward; holes 1, 2, 4 and 5 were illuminated all at once, and then individually, with > 75 responses required to progress from each stage. All animals were meeting criteria in stage 3 of rGT training after 10 days.
Second, animals were trained to associate each nose-poke hole with the reward and punishment contingencies it would maintain throughout the remainder of the experiment. This training was accomplished through 7 sessions in a forced choice version of the rGT in which all holes were programmed with their respective reward amount, punishment amount, and punishment probability (Table 1) , but only one nose poke hole was lit in each trial as opposed to the full rGT which presents the four nose poke holes lit together. The lit option varied between trials in pseudorandom order. All other functions were executed as in the full rGT described below. Beginning with the forced choice rGT, animals were divided into two equal groups, with cage mates in the same group, to counterbalance choice and nose-poke hole pairings outlined as version A and version B.
Finally, animals were given the full rGT, which recorded their choice behavior, premature responses (a measure of motor impulsivity), omissions, number of rewards earned, percent of trials rewarded, perseverative responses, and latencies to choose and reward collection (proxies of choice deliberation and motivation to consume reward). The 30 min session, as well as each trial within the session, was initiated by a nose-poke in the lit food tray. After a 5 s inter-trial interval with the tray-light off, holes 1, 2, 4, and 5 were lit simultaneously for 10 s, during which the animals could make a response choice. If a response was made into nose-poke holes 1, 2, 4, or 5 during the inter-trial interval, it was recorded as a premature response (a measure of motor impulsivity) and punished by a 5 s time-out period. A response during the 10 s stimulus duration was either rewarded or punished according to the reinforcement schedule associated with that choice, and the choice was recorded. If rewarded, the proper number of pellets was delivered to the food tray and a subsequent response at the food tray would initiate the next trial. If punished, all lights were extinguished except the light in the chosen hole, which flashed at 0.5 Hz for the duration of the time-out. Failure to respond within 10 s after stimulus illumination was measured as an omitted response (a measure of motivation), and after which another trial would begin.
The following measures for decision making were calculated at baseline and during drug tests: 1) percent choice = (number of choices made for a pellet option) / (total number of choices or responses made) × 100; 2) choice score, which is a single value calculated from the percent choice of the two advantageous options (P1 + P2) minus the percent choice of the two disadvantageous options (P3 + P4). Animals with a positive choice score were designated as "optimal", whereas animals with a negative choice score were designated as "riskpreferring". In addition, other measures analyzed were the percentage premature responses, number of omissions, number of trials completed and choice latencies and reward collection latencies.
Drugs
Rimonabant (SR141716A; 0.3, 1.0 and 3.0 mg/kg) and THC (0.5, 1.0 and 2.0 mg/kg) were generated, and kindly provided by, AbbVie and Echo Pharmaceuticals (both Weesp, the Netherlands), respectively. (+)-Amphetamine sulfate (OPG, Utrecht, the Netherlands; 1.0 mg/kg) was dissolved in sterile saline, whereas rimonabant, URB597 (Sigma Aldrich, St. Louis, MO, USA; 0.3 mg/kg), WIN55,212-2 (Tocris Bioscience, Avonmouth, UK; 0.3, 1.0 and 3.0 mg/kg), and THC were dissolved in a mixture of 96% ethanol, Tween80, and sterile saline (ratio 1:1:18) as described before (De Vries et al., 2001) . Drug doses and injection times were based on previous studies (Pattij et al., 2007a (Pattij et al., , 2007b Wiskerke et al., 2011b) : URB597 was injected 120 min prior to testing, rimonabant 45 min prior to testing, THC 30 min prior to testing, and WIN55,212-2 and amphetamine were injected 20 min before testing. Drugs were freshly prepared on each test day and injected intraperitoneally (i.p.) in a volume of 1 mL/kg bodyweight. Rimonabant, THC and WIN55,212-2 were administered according to a Latin square within-subjects design, whereas for amphetamine and URB597 half of the animals received a drug dose on the first test and vehicle on the second test day. For the other half of the animals this order was reversed. Drug challenges were conducted on Tuesdays and Fridays with baseline training sessions on the other weekdays. Prior to the first test day, all animals had been habituated twice to saline injections. Tests with the different compounds were separated by a washout period of one week, during which the animals were trained in the rGT without drug challenges.
Data analysis
Data were analyzed using IBM SPSS Statistics version 20 (IBM Corporation, Armonk, NY, USA) and were subjected to repeated measures analysis of variance (ANOVA) with drug dose and choice as within subjects variables and choice preference ('optimal' vs 'risk-preferring') as a between subjects variable. All data expressed as percentages (i.e. choice and premature responding) were arcsine transformed before analyses to limit the effect of an artificially-imposed ceiling (McDonald, 2009) . The homogeneity of variance across groups was determined using Mauchly's tests for equal variances and in case of violation of homogeneity, Huynh-Feldt epsilon (ε) adjusted degrees of freedom resulting in more conservative probability values were depicted and used for subsequent analyses. In cases of statistically significant main dose effects, further paired comparisons were conducted using paired t-tests. The level of probability for statistically significant effects was set at P = 0.05. Graphs were produced using GraphPad Prism version 5.02 for Windows (GraphPad Software, San Diego, CA, USA). 
Results
Baseline performance
Selection of animals based on their choice score during stable baseline performance yielded in total N = 20 optimal rats and N = 12 risk-preferring rats (cohort 1: n = 10 optimal and n = 6 risk-preferring rats; cohort 2: n = 10 optimal and n = 6 risk-preferring rats). Under stable baseline performance across 3 sessions, optimal animals showed a significant preference for P2 over the other pellet choice options and risk-preferring rats for P2, P3 and P4 over P1 ( Fig. 1A ; F (3,84) choice = 11.72, P < 0.001; F(3,84) choice×group = 7.72, P < 0.0001; F(1,28) group = 2.16, NS; F(2,56) session = 0.13, NS; F (6,168) session×choice×group = 1.03, NS). This group difference was also reflected in the animals' choice score across baseline sessions ( Fig. 1B; F (1,28) group = 60.26, P < 0.0001; F(2,56) session = 0.003, NS; F (2,56) session×cohort×group = 0.90, NS), with optimal animals showing significantly higher choice scores. As indicated in Table 2 , risk-preferring rats also completed significantly fewer trials at baseline (F (1,28) group = 7.47, P < 0.0001; F(2,56) session = 0.43, NS; F (2,56) session×cohort×group = 0.47, NS), likely due to the lengthy timeouts associated with the choice of the disadvantageous options of the task and earned significantly less pellets (F(1,28) group = 17.77, P < 0.0001; F(2,56) session = 1.04, NS; F(2,56) session×cohort×group = 0.42, NS). There were neither significant group differences in premature responding, omissions, and reward collection latencies, nor were there main session or main session × cohort × group interaction effects for these three variables (all F's < 2.05, NS). Finally, while groups did not differ in terms of choice latencies, there was a small and significant change in choice latencies over the three baseline sessions (F(1,28) group = 0.002, NS; F(2,56) session = 8.45, P < 0.01; F(2,56) session×cohort×group = 2.05, NS). Further comparisons revealed that collection latencies were slower in the third baseline session compared to both the first and second baseline session (baseline session 1: 1.20 ± 0.09 s; baseline session 2: 1.17 ± 0.08 s; baseline session 3: 1.30 ± 0.1 s; P < 0.05 and P < 0.0001, respectively).
During the drug testing phase, within-cohort analyses indicated no significant changes in decision making under vehicle conditions across drug challenges (cohort 1: F(6,84) test×choice×group = 0.46, NS; cohort 2: F(3,42) test×choice×group = 0.64, NS), suggesting that there was no drift in baseline behavior across drug tests. Values expressed as average (SEM). ⁎⁎ P < 0.005 compared to 'optimal' rats.
(3,42) choice×group = 5.62, P < 0.01; F(5,63) dose×choice = 0.41, NS; F (5,63) dose×choice×group = 1.36, NS; F(1,14) group = 0.47, NS). However, choice was trending towards a differential effect between the two groups, most notably in optimal animals visibly showing greater advantageous choice ( Fig. 2A, B ; F(3,42) dose×group = 2.70, P = 0.06), a result supported by a trend towards improved choice score in these rats ( Fig. 2C ; F(3,42) dose×group = 2.39, P = 0.08; F(3,42) dose = 0.60, NS; F (1,14) group = 13.81, P < 0.0001). In contrast, risk-preferring animals tended to show the opposite effect.
Auxiliary measures
Administration of rimonabant did not affect motor impulsivity ( Fig. 2D ; F(3,42) dose = 1.80, NS; F(3,42) dose×group = 0.37, NS; F (1,14) group = 0.39, NS), but did increase choice latencies in all animals (Table 4 ; F(3,42) dose = 5.79, P < 0.01; F(3,42) dose×group = 1.62, NS; F (1,14) group = 0.33, NS). This effect was greatest at the highest dose (vehicle vs 3 mg/kg: t(15) = −4.22, P < 0.01; other doses: t (15) < 1.78, NS). Rimonabant did not affect collection latencies (dose and dose × group Fs < 2.92, NS), nor the number of trials completed; there was only a main effect of group, with risk-preferring rats continuing to complete fewer trials (Table 3 ; F(1,14) group = 14.43, P < 0.01; dose and dose × group Fs < 2.51, NS). Finally, administration of rimonabant did not alter the number of omissions (Table 3; all Fs < 1.63, NS).
3.3. Effects of THC and WIN55,212-2 on rGT performance 3.3.1. Choice
The CB1 receptor agonists THC and WIN55,212-2 had no significant impact on decision making at the individual choice level (Fig. 3A, B ; THC: F(3,33) dose = 0.31, NS; F(3,33) dose×group = 0.03, NS; F (4,49) dose×choice = 0.84, NS; F(4,49) dose×choice×group = 1.36, NS; F (1,11) group = 0.56, NS; Fig. 3E, F ; WIN55,212-2: F(3,21) dose = 1.61, NS; F(3,21) dose×group = 0.52, NS; F(9,63) dose×choice = 1.67, NS; F (9,63) dose×choice×group = 1.65, NS; F(1,7) group = 1.77, NS). Choice scores trended to be differentially affected by THC but not WIN55,212-2, where risk-preferring rats appeared to have a better choice score after the highest dose ( Values expressed as averages per dose (SEM). ⁎ P < 0.05 compared to vehicle. Fig. 3 . Acute challenges with the cannabinoid CB1 receptor agonist THC shift neither choice preference (A,B) nor choice score (C), but decrease premature responding (D) in 'optimal' and 'risk-preferring' rats. Challenges with the cannabinoid CB1 receptor agonist WIN55,212-2 does not shift choice preference (E,F) or choice score (G), but exert opposite effects on premature responding (H) in 'optimal' and 'risk-preferring' rats. *P < 0.05 compared to vehicle. #P < 0.05 and ##P < 0.005 'optimal' rats versus 'risk-preferring' rats.
(3,39) dose×group = 2.57, P = 0.07; F(1,13) group = 17.54, P < 0.001; Fig. 3G ; WIN: F(3,21) dose = 2.32, NS; F(3,21) dose×group = 2.35, NS; F (1,7) group = 14.56, P < 0.01).
THC significantly reduced premature responding in all animals ( Fig. 3D ; F(3,42) dose = 5.70, P < 0.01; F(3,42) dose×group = 0.50, NS; F (1,14) group = 0.008, NS), an effect found to be significant at the highest dose (vehicle vs 0.5 mg/kg: t(15) = 1.25, NS; vehicle vs 1 mg/kg: t (15) = 0.85, NS; vehicle vs 2 mg/kg: t(15) = 4.03, P < 0.01). WIN55,212-2 visibly affected premature responding in risk-preferring rats and optimal animals ( Fig. 3H ; F(3,24) dose = 0.95, NS; F (3,24) dose×group = 0.91, NS; F(1,8) group = 9.24, P < 0.05). Post hoc ttests revealed the group difference in premature responding was significant at the middle and highest dose administered (t(14) veh = 0.57, NS; t(14) 0.5mg/kg = −0.02, NS; t(14) 1mg/kg = −1.03, P < 0.005; t (14) 2mg/kg = −3.11, P < 0.05), suggesting divergent effects of this drug were greatest at these doses.
WIN55,212-2 also increased choice latencies in all animals (Table 4 ; F(2,25) dose = 6.50, P < 0.01; F(3,42) dose×group = 2.32, NS; F (1,14) group = 2.52, NS) with the greatest effect at the highest dose (vehicle vs 0.3 mg/kg: t(15) = 0.72, NS; vehicle vs 1 mg/kg: t (15) = −1.93, P = 0.07; vehicle vs 3 mg/kg: t(15) = −3.61, P < 0.01). THC also increased choice latencies, but only in optimal animals (Table 5 ; F(2,24) dose = 2.81, NS; F(3,42) dose×group = 3.11, P < 0.05; F(1,14) group = 0.39, NS; optimal: F(2,14) dose = 6.44, P < 0.05; risk-preferring: F(3,15) dose = 0.01, NS), and exclusively at the highest dose (vehicle vs 2 mg/kg: t(9) = −3.35, P < 0.01; other doses: t < −1.009, NS). Conversely, collection latencies were unaffected by any dose of either drug (Tables 4,5 ; all dose and dose × group Fs < 2.92, NS). However, risk-preferring rats showed overall significantly faster collection latencies in the THC and WIN55,212-2 experiments (THC: F(1,14) group = 9.77, P < 0.01; WIN55,212-2: F(1,14) group = 51.39, P < 0.00001).
WIN55,212-2 dose-dependently reduced the number of trials completed by all animals (Table 4 ; F(2,26) dose = 6.78, P < 0.01; F (3,42) dose×group = 1.40, NS; F(1,14) group = 14.51, P < 0.01) and increased the number of omissions (Table 4 ; F(1,17) dose = 4.34, P ≤ 0.05; F(1,17) dose×group = 0.40, NS; F(1,14) group = 0.23, NS). These effects were significant after administration of 1 and 3 mg/kg (completed trials, vehicle vs 0.3 mg/kg: t(15) = 0.75, NS; vehicle vs 1 mg/kg: t (15) = 2.83, P < 0.05; vehicle vs 3 mg/kg: t(15) = 3.46, P < 0.01; omissions, vehicle vs 0.3 mg/kg: t(15) = −1.00, NS; vehicle vs 1 mg/ kg: t(15) = −2.19, P ≤ 0.05; vehicle vs 3 mg/kg: t(15) = −2.40, P < 0.05). In contrast, THC did not influence the number of trials completed, but risk-preferring rats consistently completed fewer trials across THC doses compared to optimal rats (Table 5 ; THC: F (1,14) group = 10.67, P < 0.01; dose and dose × group Fs < 2.51, NS). THC did not affect omissions (Table 5 ; all Fs < 1.63, NS).
Effects of URB 597 on rGT performance
The single dose of the FAAH inhibitor URB 597 had no effect on any task variable (Fig. 4, Table 6 ; F(1,22) choice = 7.92, P < 0.01; F (3,42) choice×group = 3.72, P < 0.05; choice score: F (1,14) group = 12.15, P < 0.01; trials: F(1,14) group = 12.94, P < 0.01; collection latencies: F(1,14) group = 4.15, P = 0.06; all other Fs < 1.93, NS), suggesting that acute modulation of endogenous endocannabinoid transmission does not affect cost/benefit decision making in this rat strain.
3.5. Effects of amphetamine on rGT performance 3.5.1. Choice
Amphetamine significantly impaired decision making performance (F(1,11) dose = 0.32, NS; F(1,11) dose×group = 0.35, NS; F (3,33) choice = 6.45, P < 0.01; F(3,33) choice×group = 3.70, P < 0.05; F (3,33) dose×choice = 4.23, P < 0.05; F(3,33) dose×choice×group = 3.16, P < 0.05; F(1,11) group = 2.28, NS). As decision making was differentially affected in optimal versus risk-preferring rats, subsequent analyses showed that in optimal animals amphetamine primarily increased disadvantageous choice ( Fig. 5A; F(1,8 ) dose = 0.001, NS; F (3,24) choice = 9.68, P < 0.01; F(3,24) dose×choice = 3.38, P < 0.05) by increasing choice of P4 (t(9) P4 = −2.99, P < 0.05). Risk-preferring rats' decision making was also affected by 1.0 mg/kg amphetamine ( Fig. 5A; F(1,3 ) dose = 0.25, NS; F(3,9) choice = 2.40, NS; F (3,9) dose×choice = 9.48, P < 0.01), increasing choice of P2 and P3 (t Values expressed as averages per dose (SEM). ⁎ P < 0.05 compared to vehicle.
Table 5
Auxiliary parameters after THC administration. Values expressed averages per dose (SEM). ⁎ P < 0.05 compared to vehicle.
(3) P2 = −5.03, P < 0.05; t(3) P3 = 3.98, P < 0.05). Choice score was not affected by amphetamine (Fig. 5B : F(1,11) group = 21.16, P < 0.01; F(1,11) dose = 0.034, NS; F(1,11) dose×group = 0.012, NS).
Auxiliary measures
Amphetamine did not affect premature responding ( Fig. 5C ; all Fs < 1.44, NS). Additionally, the number of completed trials was not affected by amphetamine, yet 'risk-preferring' rats completed fewer trials (Table 7 ; F(1,14) dose×group = 1.47, NS; F(1,14) group = 9.56, P < 0.01), likely due to the greater time spent in timeout as a result of choosing P4 more frequently.
Though the group difference was maintained for reward collection latencies (Table 7 ; F(1,13) group = 5.57, P < 0.05), amphetamine increased optimal animals' latency to collect reward (F(1,13) dose = 6.74, P < 0.05; F(1,13) dose×group = 34.53, P < 0.0001; optimal: F (1,8) dose = 45.42, P < 0.001; risk-preferring: F(1,5) dose = 4.39, NS). Amphetamine had no effect on the number of omissions in either group of rats (all Fs < 2.29, NS).
Discussion
The current findings indicate that risky decision making as measured in the rGT can be reliably assessed in male Wistar rats, thereby extending the utility of this model to a previously untested rat strain. Moreover, consistent with previous data, pharmacological challenges with amphetamine affected decision making and promoted preference for disadvantageous choice, particularly in animals that displayed optimal decision making. In contrast, acute administration of cannabinoid ligands did not have strong effects on choice patterns in the rGT, yet did modulate motor impulsivity. In this regard, it should be pointed out that in both cohorts, the group size of 'risk-preferring' rats was relatively small (n = 6). Thus, it should be emphasized that in some aspects the current findings could have been underpowered to fully capture drug effects in this group of rats. Further establishing the acute effects of cannabinoids in the rGT would then require training larger cohorts of animals in the task to recruit higher sample sizes of 'risk-preferring' rats.
The rGT used here was developed by Winstanley and colleagues (Zeeb et al., 2009 ) and the collective work using this model has clearly elucidated cholinergic, dopaminergic, noradrenergic and serotonergic modulation of risky decision making in various rat strains, including Long-Evans and Lister Hooded rats (Baarendse et al., 2013; Di Ciano et al., 2015; Silveira et al., 2015; Zeeb et al., 2009) . Moreover, recent work in Long-Evans rats has focused on individual differences in choice preference in this task by designating animals that prefer the more disadvantageous pellet options as 'risk-preferring' and animals that prefer the advantageous pellet options as 'optimal', and subsequently examining the interaction of these baseline preferences with cocaine self-administration behavior (Ferland and Winstanley, 2017) . Since all of our previous work on cannabinoid modulation of executive functioning was conducted in Wistar rats (Pattij et al., 2007a; Wiskerke et al., 2011b Wiskerke et al., , 2012 , the current study employed male Wistar rats in the rGT. Similar to the other rat strains, Wistar rats readily achieved stable Values expressed as averages per dose (SEM). baseline performance in the task. In addition, we designated 'risk-preferring' rats and 'optimal' rats that stably differed in terms of their preference for the disadvantageous and advantageous response options.
As an additional validation, acute challenges with 1.0 mg/kg amphetamine were used, and found to cause impaired decision making by promoting choice of the disadvantageous P4 pellet option in 'optimal' rats. This observation fits with previous data showing that amphetamine reduced preference of the advantageous P2 pellet option and increased preference for the P4 pellet option at comparable doses in Lister Hooded and Long-Evans rats (Baarendse et al., 2013; Zeeb et al., 2009) . Moreover, we found that in 'risk-preferring' rats there were modest, yet significant, increases in choice of both P2 and P3. Although further work is required, these differential responses towards amphetamine challenges might be caused by underlying differences in dopamine signaling between rats with an 'optimal' and 'risk-preferring' choice profile. In support of this notion, differences in striatal dopamine D2/ D3 transmission have been linked to individual differences in rats' preference for uncertainty in a translational betting task (Cocker et al., 2012) .
Surprisingly, amphetamine did not increase the number of premature responses in the rGT. Thus, in this respect Wistar rats differ from Lister Hooded and Long-Evans rats, which both display enhanced premature responding upon amphetamine challenges in this task (Baarendse et al., 2013; Zeeb et al., 2009) . Whereas amphetamine did decrease response latencies and thus exerted clear psychomotor effects, possibly procedural differences between the rGT and other instrumental tasks that assess premature responding such as the 5-choice serial reaction time task (Bari et al., 2008) might explain amphetamine's lack of effect in Wistar rats in the present study. In the 5-choice serial reaction time task employed in our laboratory, rats need to respond to a visual stimulus within 2 s after stimulus presentation and we have repeatedly found that amphetamine robustly increases premature responding (Van Gaalen et al., 2006; Pattij et al., 2007b; Wiskerke et al., 2011a Wiskerke et al., , 2011b ). In the current rGT, rats withhold responding for 5 s prior to stimulus presentation, and have 10 s to make a choice between the different response options. Perhaps this difference in time given to respond could have contributed to the current observations of null effects of amphetamine on premature responding in Wistar rats. Previous data support this, and show amphetamine also failed to change impulsive or premature responding in Wistar rats in an attention task with no requirements to inhibit prepotent responding (Bizot et al., 2015) .
Contrary to our hypotheses, we found no clear evidence supporting a role for the cannabinoid system in risk-based decisions. A recent study that used Long-Evans rats showed a high dose of WIN55,212-2 promoted advantageous choice in animals making suboptimal choices only (Gueye et al., 2016) . Somewhat in keeping with these data, acute THC challenges tended to promote advantageous choice in 'risk-preferring' rats (main dose × group interaction effect P = 0.07). 'Optimal' rats also showed visible improvements in choice after acute CB1 antagonism (main dose × group interaction effect P = 0.06), though both of these results are underpowered. However, outside of these subtle effects, acute modulation of the CB1 receptor and endocannabinoid system did not significantly alter risk-based decision making in the current study, Fig. 5 . Acute challenges with the psychostimulant amphetamine (1.0 mg/kg) shifts choice preferences in both 'optimal' rats and 'risk-preferring' rats (A), without affecting choice score (B) or premature responding (C). *P < 0.05, vehicle versus amphetamine. Values expressed as averages per dose (SEM). ⁎⁎ P < 0.005 compared to respective vehicle.
an effect at odds with human literature in which acute doses impaired decision making (Bolla et al., 2005) . Additional data have shown acute THC exposure in humans induced risky choice in laboratory tasks in frequent marijuana users (Lane and Cherek, 2002; Lane et al., 2005) . However, these experiments were conducted in subjects with a history of marijuana use, which may have influenced the effect of THC on decision making parameters. Furthermore, other studies have shown that acute THC administration produced no impairments in recreational or heavy cannabis users (Ramaekers et al., 2006; Cousijn et al., 2013) . The mixed effects seen in humans may be due to individual differences in activation of brain regions important for reward evaluation and decision making (Cousijn et al., 2013) , suggesting differences in reward processing may explain discrepancies in responding to THC. Though our individual differences results are not significant, they would suggest this possibility merits further investigation with a greater cohort of rats that undergo both acute and chronic THC treatment. Interestingly, previous work has shown acute THC administration can negatively impact other facets of cognition, including working memory (Morgan et al., 2010) , cognitive flexibility as measured by task switching (Anderson et al., 2011) , and emotional processing (Hindocha et al., 2015) . Although decision making relies upon these cognitive faculties, it is possible the rGT did not actively recruit them at the time of the drug challenge. Clinical studies employing cognitive tasks require subjects to learn the paradigm within a session, during which time the individual is "exploring" rules and strategies (Daw et al., 2006) . In contrast, we tested animals after acquisition of stable task performance, at which point knowledge of the contingencies is established and a choice strategy is being "exploited" (Daw et al., 2006; De Visser et al., 2011) , which may be less vulnerable to acute cannabinoid manipulation. Furthermore, previous work investigating the effects of THC on motor impulsivity found that only repeated, chronic administration of the drug potentiated behavioral disinhibition, whereas acute and limited chronic dosing had no effect (Irimia et al., 2015) . Therefore, acute CB1 activation and antagonism may not affect decision making preferences, but chronic manipulations could impair task performance. Future studies should take into account length of THC experience (i.e. acute versus chronic dosing), and time of administration (task acquisition versus performance) to further explore how CB1 activity may influence risk-based decision making.
Other task parameters, such as choice latencies, number of trials completed and omissions, were affected by rimonabant, THC and/or WIN55,212-2 in a similar fashion compared to previous data (Arguello and Jentsch, 2004; Pattij et al., 2007a; Silveira et al., 2017; Wiskerke et al., 2011b) . Thus, suboptimal dose ranges seem unlikely to explain the lack of effects of these direct cannabinoid CB1 receptor agonists on choice behavior. Rather, these results suggest that acute modulation of CB1 receptor activity may affect distinct aspects of cognition. Indeed, THC reduced impulsive responding in all animals, whereas the potent CB1 agonist WIN55,212-2 potentiated premature responding in riskpreferring rats, yet reduced it in optimal animals. Nonetheless, contrasting our previous data (Pattij et al., 2007a) , rimonabant did not affect impulsive responding in the rGT. As discussed earlier the task structure of the current task differs from other tasks measuring impulsive responding, which may impact the interpretation of our current data in comparison to data obtained in the 5-choice serial reaction time task with cannabinoid ligands previously (Pattij et al., 2007a; Wiskerke et al., 2011b) . Regardless, these results suggest greater CB1 activation may produce unique results dependent upon pre-existing differences in reward processing. It is well documented that CB1 receptor activation influences dopamine release (for review see Bloomfield et al., 2016) , including within the nucleus accumbens, an area in which dopaminergic activity correlates with decision-making preferences (Sugam et al., 2012) . Furthermore, dopaminergic transmission within the nucleus accumbens has been shown to influence impulsive responding (Cole and Robbins, 1989; Besson et al., 2010; Moreno et al., 2013; Pattij et al., 2007b) . Although speculative, the high dose of THC given may reduce accumbal dopamine release in all animals , whereas more direct activation of the CB1 receptor may differentially affect release depending on baseline differences in dopaminergic activity between risk-preferring and optimal animals. Future studies are required to determine the effect of CB1 receptor modulation on dopamine release in reward centers or interactions with other neurotransmitter systems such as glutamate (Colizzi et al., 2016) , the latter which may also impact impulsive responding (Winstanley, 2011) .
Although WIN55,212-2 potentiated impulsive action in risk-preferring animals, it dose-dependently reduced motivation as exhibited by increased omissions, reduced number of trials, and increased choice latency in all rats. The dissociation between measures of motivation and premature responding may reflect recruitment of separate networks affected by CB1 activation (Oleson et al., 2012) .
In conclusion, these data show acute modulation of the CB1 receptor has dissociated effects on various aspects of cognitive performance, potentially tapping into distinct mechanisms governing decision making, impulse control, and motivation. As such, acute challenges with cannabinoid ligands did not strongly affect decision making, yet impacted impulsive behavior and measures of motivation. The effects observed here add to an existing body of research exploring the role of the endocannabinoid system in cognition, and may shed light on how the recruitment of the CB1 receptor by exogenous cannabinoids may contribute to the expression of various behavioral phenotypes implicated in psychiatric disease.
